Dr. von Eschenbach receives distinguished service award
FDA Commissioner Andrew C. von Eschenbach, MD, recently received the American Association for Cancer Research Distinguished Service Award for exemplary leadership as director of the National Cancer Institute during a time of flourishing scientific and technological advances with gradually diminishing resources.
FDA Commissioner Andrew C. von Eschenbach, MD, recently received the American Association for Cancer Research Distinguished Service Award for exemplary leadership as director of the National Cancer Institute during a time of flourishing scientific and technological advances with gradually diminishing resources.
During his 5-year tenure, Dr. von Eschenbach fostered new and productive interagency agreements among FDA and the Centers for Medicare & Medicaid Services, which streamlined the development and delivery of new medicines to seriously ill patients with cancer, the association said.
A nationally recognized urologic surgeon and oncologist, founding member of C-Change, former president-elect of the American Cancer Society, and three-time cancer survivor, Dr. von Eschenbach has made an impact on the fight against cancer that extends well beyond the clinical and academic communities.
Toripalimab plus axitinib approved in China for renal cell carcinoma
April 11th 2024The approval is based on findings from the phase 3 RENOTORCH trial, which showed that toripalimab plus axitinib prolonged progression-free survival and improved the objective response rate in patients with advanced RCC compared with sunitinib.
